NCT07134712Not yet recruitingPhase 2
Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II
Safety and Efficacy Study of Intravenous Administration of MiSaver (Umbilical Cord Blood Derived Nucleated Cells) After Acute Myocardial Infarction
Source: ClinicalTrials.gov · Last updated 11 Mar 2026
Brief summary (registry, in English)
This trial is a Phase II, multicenter clinical study. The purpose of this trial is to evaluate the safety and efficacy of MiSaver, a cellular therapy product, in patients who have experienced an acute myocardial infarction (AMI). Specifically, the study aims to assess the improvement in left ventricular function of the heart following the administration of MiSaver, as well as to determine the safety of using stem cell therapy in these patients. This trial will employ a single-blind design (subject-blinded), meaning that the participants will not be aware of whether they are receiving MiSaver or standard treatment, while the researchers will have this information. This design helps ensure transparency and adherence to ethical standards while also providing valuable clinical insights. By utilizing randomization, we can enhance the reliability and comparability of the study results. A portion of the participants will receive MiSaver, while the others will undergo standard treatment. This allows for a direct comparison of the two therapeutic approaches to determine their respective efficacy. The primary objective of this trial is to evaluate the safety and efficacy of MiSaver, in the treatment of patients with acute myocardial infarction (AMI). To achieve this, we will collect comprehensive participant data, including assessments of cardiac function, records of cardiac events, and quality-of-life surveys. By analyzing these data, we aim to gain a deeper understanding of the benefits and limitations of this treatment approach.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 102 (estimated)
- First submitted
- 14 Aug 2025
- Start date
- 30 Mar 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- HONYA Medical Co Ltd
- Diseases
- Coronary artery disease
- NCT number
- NCT07134712
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 102
- From 30 Mar 2026 to the primary completion date, 31 Dec 2027
- 4 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients diagnosed as needing coronary artery bypass surgery or potentially requiring coronary revascularization surgery within the next 6 months.
- Patients with autoimmune diseases or those who have already received immunotherapy.
- Patients who have undergone tumor treatment or require immunosuppressive therapy within the last three years.
- Patients who have previously received growth factors, cytokines, gene therapy, or stem cell therapy.
- Inability to sign the consent form or comply with outpatient follow-up after infusion therapy.
Other illness
- Immunodeficiency diseases caused by infection , such as Human Immunodeficiency Virus (HIV).
- Life-threatening arrhythmias.
- Malignant tumors, including all categories and cancer conditions.
- Hematologic disorders or other severe organ diseases with an expected survival of less than one year.
- History of transfusion reactions.
- Patients with a known allergy to this product or its excipients (e.g., dimethyl sulfoxide, cell preservation solution).
Lab values
- Chronic kidney disease (eGFR \< 30 mL/min/1.73m²) or patients undergoing dialysis.
- Liver dysfunction (bilirubin \> 2.5 mg/dL or transaminases \> 5x the upper limit of normal).
Age
- Age \< 45 years, BMI \> 32.
Other
- Women who are planning to become pregnant, are pregnant, or are breastfeeding
- Severe aortic or mitral valve stenosis.
- Recipients of bone marrow or organ transplants.
- Subjects participating in more than one clinical trial.
Who the study is looking for
- Age ≥ 45 years, BMI ≤ 32
- Patients diagnosed with acute myocardial infarction by a cardiologist, within 36 hours to 7 days post-diagnosis, and able to complete cell infusion within this period.
- Left ventricular ejection fraction (LVEF) ≤ 45%, hemodynamically stable patients who do not require vasopressor support within 24 hours.
- Patients with a history of coronary artery disease, who have previously undergone percutaneous coronary intervention or coronary artery bypass graft surgery, may also be included upon evaluation by a cardiologist.
- Patients deemed unsuitable for percutaneous coronary intervention or coronary artery bypass graft surgery by a cardiologist.
- Must agree to sign the informed consent form.
- Subjects must use effective contraception during the study observation period and for 6 months after its conclusion to ensure no pregnancy occurs during the study. (Primarily for women of childbearing potential).
- Agree to and comply with the required outpatient visits and examinations during the study observation period.
Age in the registry: 45 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Flinders Medical Centre Coordinator of this site? Confirm its status | Bedford Park | Australia | Unknown status |
| Mackay Memorial Hospital - Hsinchu Branch Coordinator of this site? Confirm its status | Hsinchu | Taiwan | Unknown status |
| Kaohsiung Medical University Chung-Ho Memorial Hospital Coordinator of this site? Confirm its status | Kaohsiung City | Taiwan | Unknown status |
| Chung Shan Medical University Hospital Daqing Branch Coordinator of this site? Confirm its status | Taichung | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.